- Home
- FENC vs SGMO Comparison
FENC vs SGMO Comparison
Compare FENC & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- SGMO
- Stock Information
- Founded
- FENC 1996
- SGMO 1995
- Country
- FENC United States
- SGMO United States
- Employees
- FENC N/A
- SGMO N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FENC Health Care
- SGMO Health Care
- Exchange
- FENC Nasdaq
- SGMO Nasdaq
- Market Cap
- FENC 172.8M
- SGMO 180.5M
- IPO Year
- FENC 2001
- SGMO 2000
- Fundamental
- Price
- FENC $6.07
- SGMO $2.82
- Analyst Decision
- FENC Strong Buy
- SGMO Buy
- Analyst Count
- FENC 2
- SGMO 3
- Target Price
- FENC $14.00
- SGMO $7.00
- AVG Volume (30 Days)
- FENC 173.1K
- SGMO 5.8M
- Earning Date
- FENC 11-07-2024
- SGMO 11-12-2024
- Dividend Yield
- FENC N/A
- SGMO N/A
- EPS Growth
- FENC N/A
- SGMO N/A
- EPS
- FENC N/A
- SGMO N/A
- Revenue
- FENC $49,348,000.00
- SGMO $52,291,000.00
- Revenue This Year
- FENC $97.94
- SGMO N/A
- Revenue Next Year
- FENC $11.50
- SGMO $11.46
- P/E Ratio
- FENC N/A
- SGMO N/A
- Revenue Growth
- FENC 278.09
- SGMO N/A
- 52 Week Low
- FENC $3.96
- SGMO $0.30
- 52 Week High
- FENC $11.92
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- FENC 61.50
- SGMO 70.33
- Support Level
- FENC $5.77
- SGMO $1.80
- Resistance Level
- FENC $6.35
- SGMO $2.08
- Average True Range (ATR)
- FENC 0.39
- SGMO 0.25
- MACD
- FENC -0.02
- SGMO 0.04
- Stochastic Oscillator
- FENC 51.62
- SGMO 98.08
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.